Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)

Babu,Geethu; Kainickal,Cessal Thommachan

doi:10.3892/mco.2020.2197

Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)

Authors:
- Geethu Babu
- Cessal Thommachan Kainickal
View Affiliations

Affiliations: Department of Radiation Oncology, Regional Cancer Center, Medical College Campus, Trivandrum, 695011 Kerala, India
Published online on: December 24, 2020 https://doi.org/10.3892/mco.2020.2197
Article Number: 35

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of differentiated thyroid cancer (DTC) has increased over the last few decades, though it remains to be a rare disease. The prognosis of DTC is excellent; its treatment includes surgery (near‑/total thyroidectomy), which is usually followed by remnant thyroid bed ablation using radio‑iodine, as well as a risk‑stratified follow‑ups, including hormone replacement. Treatment of patients who are non‑responsive to radioactive iodine (RAI) remains a challenge. Targeted therapies for RAI refractory DTC act primarily through inhibition of cell proliferation, survival and angiogenesis. Tyrosine kinase inhibitors (TKI) have achieved prolonged responses and improved progression‑free survival, thereby representing a shift in the treatment of advanced thyroid cancer. There will be number of targeted treatment options for this patient population in the near future. Evidence regarding which drug should be used first and whether there is crossover drug resistance between these drugs is still lacking. Clinicians should be able to choose precisely which patients should be treated with novel targeted therapies after taking into account the following facts: i) TKIs have still not demonstrated a survival benefit. ii) The adverse effects of long‑lasting treatment with TKIs could worsen quality of life, which is mostly excellent in these patients before starting treatment with these agents.

View Figures

View References

1	Alonso-Gordoa T, Díez JJ, Durán M and Grande E: Advances in thyroid cancer treatment: Latest evidence and clinical potential. Ther Adv Med Oncol. 7:22–38. 2015.PubMed/NCBI View Article : Google Scholar
2	Hegedüs L: Clinical practice. The thyroid nodule. N Engl J Med. 351:1764–1771. 2004.PubMed/NCBI View Article : Google Scholar
3	GLOBOCAN 2012 [Internet]. Available from: urihttp://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=89356&title=India&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute%C2%A0simplehttp://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=89356&title=India&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute%C2%A0. Accessed September 10, 2018.
4	Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Maréchaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi J, Schlumberger M, Wémeau JL, et al: Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 150:133–139. 2004.PubMed/NCBI View Article : Google Scholar
5	Benbassat CA, Mechlis-Frish S and Hirsch D: Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 30:1088–1095. 2006.PubMed/NCBI View Article : Google Scholar
6	Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F and Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. Clin Endocrinol Metab. 91:2892–2899. 2006.PubMed/NCBI View Article : Google Scholar
7	Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S and Falchook G: BRAF Inhibitors: Experience in thyroid cancer and general review of toxicity. Horm Cancer. 6:21–36. 2015.PubMed/NCBI View Article : Google Scholar
8	Worden F: Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 6:267–279. 2014.PubMed/NCBI View Article : Google Scholar
9	Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, et al: A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 121:2749–2756. 2015.PubMed/NCBI View Article : Google Scholar
10	Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, et al: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.PubMed/NCBI View Article : Google Scholar
11	Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, et al: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 372:621–630. 2015.PubMed/NCBI View Article : Google Scholar
12	St Bernard R, Zheng L, Liu W, Winer D, Asa SL and Ezzat S: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 146:1145–1153. 2005.PubMed/NCBI View Article : Google Scholar
13	Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJL, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC and Franklyn JA: Pituitary tumor transforming gene and fibroblast growth factor-2 expression: Potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab. 88:2341–2347. 2003.PubMed/NCBI View Article : Google Scholar
14	Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008.PubMed/NCBI View Article : Google Scholar
15	Kim KB, Chesney J, Robinson D, Gardner H, Shi MM and Kirkwood JM: Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 17:7451–7461. 2011.PubMed/NCBI View Article : Google Scholar
16	Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, et al: Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 75:213–221. 2017.PubMed/NCBI View Article : Google Scholar
17	Stjepanovic N and Capdevila J: Multikinase inhibitors in the treatment of thyroid cancer: Specific role of lenvatinib. Biologics. 8:129–139. 2014.PubMed/NCBI View Article : Google Scholar
18	Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379. 2005.PubMed/NCBI View Article : Google Scholar
19	Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, et al: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 92:2840–2843. 2007.PubMed/NCBI View Article : Google Scholar
20	Cabanillas ME, McFadden DG and Durante C: Thyroid cancer. Lancet. 388:2783–2795. 2016.PubMed/NCBI View Article : Google Scholar
21	Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, et al: Antiangiogenic tyrosine kinase inhibitors: Occurrence and risk factors of hemoptysis in refractory thyroid cancer. J Clin Endocrinol Metab. 101:2733–2741. 2016.PubMed/NCBI View Article : Google Scholar
22	Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B and Cabanillas ME: Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 24:918–922. 2014.PubMed/NCBI View Article : Google Scholar
23	Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, et al: Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 368:623–632. 2013.PubMed/NCBI View Article : Google Scholar
24	Rothenberg SM, McFadden DG, Palmer EL, Daniels GH and Wirth LJ: Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 21:1028–1035. 2015.PubMed/NCBI View Article : Google Scholar
25	Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, et al: Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol. 13:897–905. 2012.PubMed/NCBI View Article : Google Scholar
26	Bible KC, Cote GJ, Demeure MJ, Elisei R, Jhiang S and Ringel MD: International Thyroid Oncology Group Correlative Science Committee. Correlative studies in clinical trials: A position statement from the international thyroid oncology group. J Clin Endocrinol Metab. 100:4387–4395. 2015.PubMed/NCBI View Article : Google Scholar
27	Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ and Brose MS: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 26:4714–4719. 2008.PubMed/NCBI View Article : Google Scholar
28	Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 27:1675–1684. 2009.PubMed/NCBI View Article : Google Scholar
29	Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW and Kapiteijn E: Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial. Eur J Endocrinol. 167:643–650. 2012.PubMed/NCBI View Article : Google Scholar
30	Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R and Nutting CM: Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol. 165:315–322. 2011.PubMed/NCBI View Article : Google Scholar
31	Keefe SM, Troxel AB, Rhee S, Puttaswamy K, O'Dwyer PJ, Loevner LA, Mandel J and Brose MS: Phase II trial of sorafenib in patients with advanced thyroid cancer. J Clin Oncol. 29 (Suppl 15)(S5562)2011.
32	Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, et al: Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 161:923–931. 2009.PubMed/NCBI View Article : Google Scholar
33	Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, et al: A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 29 (15 Suppl)(S5503)2011.
34	Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Korte SH, Smith-Marrone S, Xiao H, Ghossein RA, Fagin JA, et al: A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. J Clin Oncol. 30 (15 Suppl)(S5514)2012.
35	Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Lipson BL, Kurz S, Fagin JA and Pfister DG: Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol. 31 (Suppl 15)(S6024)2013.
36	Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, et al: Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 96:997–1005. 2011.PubMed/NCBI View Article : Google Scholar